ImmVira’s MVR-T3011 Obtained NMPA’s Approval for Intravenous Administration (IV) Phase I Clinical Trial
SHENZHEN, China, Aug. 6, 2021 /PRNewswire/ — ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval from National Medical Products Administration (“NMPA”) for clinical trial for treatments using intravenous…
Comments Off on ImmVira’s MVR-T3011 Obtained NMPA’s Approval for Intravenous Administration (IV) Phase I Clinical Trial